CN102851291B - 包含抗微小rna反义寡核苷酸的药物组合物 - Google Patents
包含抗微小rna反义寡核苷酸的药物组合物 Download PDFInfo
- Publication number
- CN102851291B CN102851291B CN201210247597.0A CN201210247597A CN102851291B CN 102851291 B CN102851291 B CN 102851291B CN 201210247597 A CN201210247597 A CN 201210247597A CN 102851291 B CN102851291 B CN 102851291B
- Authority
- CN
- China
- Prior art keywords
- oligonucleotide
- lna
- mir
- xxxxxx
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Abstract
Description
寡聚体与miR-122RNA互补物 | Tm |
SPC3372+miR-122a,RNA | 69℃ |
SPC3648+miR-122a,RNA | 74℃ |
SPC3649+miR-122a,RNA | 79℃ |
寡聚体与DNA互补物 | Tm |
SPC3372+122R,DNA | 57℃ |
SPC3649+122R,DNA | 66℃ |
设计 | miR-155 | miR-19b | miR-122a |
新增强设计 | *** | *** | 无数据 |
新设计 | *** | *** | *** |
完全互补物,LNA_3 | ** | *** | ** |
完全互补物,阻断 | ** | ** | ** |
完全互补物,缺口 | * | 不显著 | 不显著 |
Claims (9)
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78899506P | 2006-04-03 | 2006-04-03 | |
US60/788,995 | 2006-04-03 | ||
DKPA200600478 | 2006-04-03 | ||
DKPA200600478 | 2006-04-03 | ||
US79681306P | 2006-05-01 | 2006-05-01 | |
DKPA200600615 | 2006-05-01 | ||
US60/796,813 | 2006-05-01 | ||
DKPA200600615 | 2006-05-01 | ||
US83871006P | 2006-08-18 | 2006-08-18 | |
US60/838,710 | 2006-08-18 | ||
DKPA200601401 | 2006-10-30 | ||
DKPA200601401 | 2006-10-30 | ||
CNA2007800158808A CN101437942A (zh) | 2006-04-03 | 2007-03-30 | 包含抗微小rna反义寡核苷酸的药物组合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007800158808A Division CN101437942A (zh) | 2006-04-03 | 2007-03-30 | 包含抗微小rna反义寡核苷酸的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102851291A CN102851291A (zh) | 2013-01-02 |
CN102851291B true CN102851291B (zh) | 2016-03-09 |
Family
ID=43062722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210247597.0A Active CN102851291B (zh) | 2006-04-03 | 2007-03-30 | 包含抗微小rna反义寡核苷酸的药物组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8163708B2 (zh) |
EP (4) | EP3431602A1 (zh) |
CN (1) | CN102851291B (zh) |
EA (4) | EA201100813A1 (zh) |
ES (1) | ES2569558T3 (zh) |
MY (1) | MY162210A (zh) |
NZ (1) | NZ571569A (zh) |
PL (1) | PL2666859T3 (zh) |
SG (2) | SG10201406016SA (zh) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008306327B2 (en) | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
WO2009091972A2 (en) * | 2008-01-18 | 2009-07-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
EP2268811A1 (en) * | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
JP2012502991A (ja) | 2008-09-22 | 2012-02-02 | アールエックスアイ ファーマシューティカルズ コーポレーション | 皮膚適用におけるrna干渉 |
WO2010122538A1 (en) * | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
US9334495B2 (en) * | 2009-11-25 | 2016-05-10 | Elitechgroup B.V. | Minor groove binder (MGB)-oligonucleotide miRNA antagonists |
EP2539357B1 (en) | 2010-02-26 | 2017-06-14 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets |
WO2011119871A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Phrmaceuticals Corporation | Rna interference in ocular indications |
BR112012024049A2 (pt) | 2010-03-24 | 2017-03-01 | Rxi Pharmaceuticals Corp | interferência de rna em indicações dérmicas e fibróticas |
AU2011232669B2 (en) * | 2010-03-26 | 2016-08-25 | The Ohio State University | Materials and methods related to modulation of mismatch repair and genomic stability by miR-155 |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
EP2638163B1 (en) | 2010-11-12 | 2017-05-17 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
ES2868950T3 (es) * | 2011-04-25 | 2021-10-22 | Sanofi Sa | Compuestos de microARN y métodos para modular la actividad de miR-21 |
WO2013013165A2 (en) * | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
BR112014008925A2 (pt) * | 2011-10-11 | 2020-10-27 | The Brigham And Women's Hospital, Inc. | micro rnas em distúrbios de neurodegenerativos |
CA3077746A1 (en) * | 2011-10-19 | 2013-04-25 | Council Of Scientific And Industrial Research (C.S.I.R.) | Biomarkers useful for detection of types, grades and stages of human breast cancer |
UA117098C2 (uk) | 2012-04-25 | 2018-06-25 | Рег'Юлес Терап'Ютікс Інк. | Сполука, що містить модифікований олігонуклеотид |
JP2015518712A (ja) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | Mecp2発現を調節するための組成物及び方法 |
EA201492120A1 (ru) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии atp2a2 |
AP2014008100A0 (en) | 2012-05-16 | 2014-12-31 | Gen Hospital Corp | Compositions and methods for modulating hemoglobingene family expression |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
WO2014076195A1 (en) * | 2012-11-15 | 2014-05-22 | Santaris Pharma A/S | Oligonucleotide conjugates |
WO2014179445A1 (en) | 2013-05-01 | 2014-11-06 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
MX371093B (es) | 2013-05-01 | 2020-01-16 | Regulus Therapeutics Inc | Compuestos de microarn y metodos para modular al mir-122. |
CN104031987B (zh) * | 2014-05-12 | 2016-08-31 | 贵州省人民医院 | miRNA在心肌纤维化疾病治疗中的应用 |
CA2966044A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
EP3218486A1 (en) * | 2014-11-10 | 2017-09-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Combination long acting compositions and methods for hepatitis c |
US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
CN105087477A (zh) * | 2015-05-21 | 2015-11-25 | 王松灵 | miR-21反义核苷酸修饰的骨髓间充质干细胞的用途 |
AU2016270434B2 (en) * | 2015-06-05 | 2019-07-11 | MiRagen Therapeutics, Inc. | miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL) |
ES2877411T3 (es) * | 2015-08-26 | 2021-11-16 | Univ Kaohsiung Medical | Composición antisentido de microARN-328 y uso terapéutico |
JP6666002B2 (ja) | 2015-10-07 | 2020-03-13 | 国立大学法人京都大学 | Tdp−43プロテノパシーの予防又は治療用組成物 |
CN107034216A (zh) * | 2016-02-04 | 2017-08-11 | 中国科学技术大学 | miRancer分子的设计与应用 |
MX2019005101A (es) | 2016-11-01 | 2019-08-22 | Univ New York State Res Found | Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. |
WO2018170759A1 (zh) * | 2017-03-22 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | 重组Ad-140-148a-185-Tud腺病毒及其构建和应用 |
WO2019000147A1 (zh) * | 2017-06-26 | 2019-01-03 | 深圳市博奥康生物科技有限公司 | 一种有效抑制人mir-148a、mir-152和mir-185表达的tud rna及其应用 |
WO2019000151A1 (zh) * | 2017-06-26 | 2019-01-03 | 深圳市博奥康生物科技有限公司 | 用于同步抑制三种微小rna表达的重组腺相关病毒 |
WO2019000143A1 (zh) * | 2017-06-26 | 2019-01-03 | 深圳市博奥康生物科技有限公司 | 一种敲减miRNA表达的重组腺相关病毒 |
EP3790968A1 (en) * | 2018-05-11 | 2021-03-17 | Alpha Anomeric SAS | Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides |
US20220233570A1 (en) | 2019-05-16 | 2022-07-28 | Aptatargets, S.L. | Treatment of ischemic stroke with aptamers targeting tlr-4 |
EP3990028A4 (en) | 2019-06-26 | 2023-08-09 | Biorchestra Co., Ltd. | MICELLAR NANOPARTICLES AND ASSOCIATED USES |
WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
WO2005061710A1 (en) * | 2003-12-23 | 2005-07-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4914210A (en) * | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
US4962029A (en) * | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
WO2002081494A1 (en) | 2001-03-26 | 2002-10-17 | Sirna Therapeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
JPH06311885A (ja) | 1992-08-25 | 1994-11-08 | Mitsubishi Kasei Corp | C型肝炎ウイルス遺伝子に相補的なアンチセンス化合物 |
US6433159B1 (en) * | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
US6423489B1 (en) * | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
DE69330372T2 (de) * | 1992-09-10 | 2002-03-14 | Isis Pharmaceuticals Inc | ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN |
JPH10503364A (ja) | 1994-05-10 | 1998-03-31 | ザ ジェネラル ホスピタル コーポレーション | C型肝炎ウイルスのアンチセンス阻害 |
DK0832069T3 (da) * | 1995-06-07 | 2003-04-22 | Pfizer | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) |
SK65499A3 (en) * | 1996-11-27 | 2001-05-10 | Pfizer | Apo b-secretion/mtp inhibitory amides |
TR199902561T2 (xx) * | 1997-03-05 | 2000-02-21 | Ribogene, Inc. | Hepatit C vir�s replikasyonunun se�ici bi�imde engelleyen maddelerin belirlenmesi i�in yeni tarama y�ntemleri |
CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
CN1350542A (zh) | 1999-03-18 | 2002-05-22 | 埃克西库恩公司 | 木-lna类似物 |
ATE332909T1 (de) | 1999-03-24 | 2006-08-15 | Exiqon As | Verbesserte synthese für 2.2.1.öbicyclo- nukleoside |
ATE356824T1 (de) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-ribo-lna analoge |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
JP2003511016A (ja) | 1999-10-04 | 2003-03-25 | エクシコン エ/エス | オリゴヌクレオチドを補充する高親和性rnアーゼhの設計 |
AU7406600A (en) * | 1999-10-04 | 2001-05-10 | Exiqon A/S | A method of increasing the specificity of oxy-lna oligonucleotides |
IL139450A0 (en) | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
WO2002028875A2 (en) | 2000-10-04 | 2002-04-11 | Cureon A/S | Improved synthesis of purine locked nucleic acid analogues |
WO2002098370A2 (en) * | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
US20030125241A1 (en) | 2001-05-18 | 2003-07-03 | Margit Wissenbach | Therapeutic uses of LNA-modified oligonucleotides in infectious diseases |
WO2003070750A2 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc | Rna interference mediated inhibition of hepatitis c virus |
EP1409497B1 (en) | 2001-07-12 | 2005-01-19 | Santaris Pharma A/S | Method for preparation of lna phosphoramidites |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
WO2003029459A2 (en) | 2001-09-28 | 2003-04-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Micro-rna molecules |
CA2484526C (en) | 2002-05-08 | 2009-10-13 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
UA79300C2 (en) * | 2002-08-12 | 2007-06-11 | Janssen Pharmaceutica Nv | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
AU2003261434A1 (en) * | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
US7087229B2 (en) * | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
EP1569695B1 (en) | 2002-11-13 | 2013-05-15 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
DK2752488T3 (da) | 2002-11-18 | 2020-04-20 | Roche Innovation Ct Copenhagen As | Antisense-design |
US8124582B2 (en) * | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
FR2848572B1 (fr) * | 2002-12-12 | 2005-12-09 | Univ Joseph Fourier | Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices |
AU2004215097A1 (en) | 2003-02-10 | 2004-09-10 | National Institute Of Advanced Industrial Science And Technology | Regulation of gene expression by DNA interference |
JP4503590B2 (ja) | 2003-02-10 | 2010-07-14 | サンタリス ファーマ アー/エス | サバイビン発現を調整するためのオリゴマー化合物 |
EP1668145A4 (en) | 2003-08-07 | 2010-03-10 | Avi Biopharma Inc | SENSE ANTIVIRUS COMPOUND AND METHOD FOR TREATING SSRNA VIRUS INFECTION |
US20050142581A1 (en) | 2003-09-04 | 2005-06-30 | Griffey Richard H. | Microrna as ligands and target molecules |
GB2424887B (en) | 2003-11-26 | 2008-05-21 | Univ Massachusetts | Sequence-specific inhibition of small RNA function |
UA83510C2 (en) | 2003-12-09 | 2008-07-25 | Янссен Фармацевтика Н.В. | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b |
WO2005078139A2 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
US20050182005A1 (en) * | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
US7772389B2 (en) * | 2004-02-13 | 2010-08-10 | Rockefeller University | Anti-microRNA oligonucleotide molecules |
CN1961081B (zh) | 2004-04-07 | 2012-09-05 | 埃克斯魁恩公司 | 用于定量微rna和小干扰rna的新方法 |
US7365058B2 (en) * | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
JP2007533324A (ja) | 2004-04-20 | 2007-11-22 | ゲナコ・バイオメデイカル・プロダクツ・インコーポレイテツド | ncRNAを検出する方法 |
DK1747023T4 (en) | 2004-05-04 | 2016-05-02 | Univ Leland Stanford Junior | Methods and compositions for reducing the HCV viral genome amounts in a target cell |
WO2006093526A2 (en) | 2004-07-21 | 2006-09-08 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
US20080213891A1 (en) | 2004-07-21 | 2008-09-04 | Alnylam Pharmaceuticals, Inc. | RNAi Agents Comprising Universal Nucleobases |
FR2873694B1 (fr) | 2004-07-27 | 2006-12-08 | Merck Sante Soc Par Actions Si | Nouveaux aza-indoles inhibiteurs de la mtp et apob |
AU2005330637B2 (en) | 2004-08-04 | 2012-09-20 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
EP2990410A1 (en) * | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
DK2997980T3 (en) | 2004-08-10 | 2018-03-26 | Kastle Therapeutics Llc | PROCEDURES FOR MODULATING LIPROPROTEIN AND CHOLESTEROL LEVELS |
EP1791954A1 (en) | 2004-09-07 | 2007-06-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial |
CN101133074B (zh) | 2004-09-24 | 2012-05-30 | 阿尔尼拉姆医药品有限公司 | APOB的RNAi调节及其用途 |
EP2322616A1 (en) | 2004-11-12 | 2011-05-18 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US20060134189A1 (en) | 2004-11-17 | 2006-06-22 | Protiva Biotherapeutics, Inc | siRNA silencing of apolipoprotein B |
US20060185027A1 (en) * | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
US20070099196A1 (en) | 2004-12-29 | 2007-05-03 | Sakari Kauppinen | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs |
CA2605510C (en) | 2005-04-19 | 2013-12-24 | Surface Logix, Inc. | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion |
US20060265771A1 (en) * | 2005-05-17 | 2006-11-23 | Lewis David L | Monitoring microrna expression and function |
US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
CA2618995A1 (en) | 2005-08-10 | 2007-02-22 | The Rockefeller University | Antagomirs for use in inhibiting mir-122 |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
US20090203893A1 (en) | 2005-08-29 | 2009-08-13 | Regulus Therapeutics, Llc | Antisense compounds having enhanced anti-microrna activity |
AU2006284855B2 (en) * | 2005-08-29 | 2011-10-13 | Regulus Therapeutics Inc. | Methods for use in modulating miR-122a |
WO2007031081A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US20090326041A1 (en) | 2006-05-05 | 2009-12-31 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
DK2066684T3 (da) | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5´-Modificerede bicycliske nukleinsyreanaloge |
US20080199961A1 (en) | 2006-08-25 | 2008-08-21 | Avi Biopharma, Inc. | ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS |
CA2662978A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
MX2009002856A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Conjugados polimericos que contienen porciones cargadas positivamente. |
EP2090665A2 (en) | 2006-10-20 | 2009-08-19 | Exiqon A/S | Novel human microRNAs associated with cancer |
WO2008057234A2 (en) | 2006-10-24 | 2008-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of t cell signaling threshold and t cell sensitivity to antigens |
JP2010509923A (ja) | 2006-11-23 | 2010-04-02 | ミルクス セラピューティクス アンパーツゼルスカブ | 標的rnaの活性を変化させるためのオリゴヌクレオチド |
WO2008074328A2 (en) | 2006-12-21 | 2008-06-26 | Exiqon A/S | Microrna target site blocking oligos and uses thereof |
DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
WO2008124384A2 (en) | 2007-04-03 | 2008-10-16 | Aegerion Pharmaceuticals, Inc. | Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c |
AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
US20090082297A1 (en) * | 2007-06-25 | 2009-03-26 | Lioy Daniel T | Compositions and Methods for Regulating Gene Expression |
WO2009032083A1 (en) | 2007-08-29 | 2009-03-12 | President And Fellows Of Harvard College | Methods of increasing gene expression through rna protection |
AU2008306327B2 (en) * | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
EP2268811A1 (en) * | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
WO2010122538A1 (en) * | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
-
2007
- 2007-03-30 SG SG10201406016SA patent/SG10201406016SA/en unknown
- 2007-03-30 EA EA201100813A patent/EA201100813A1/ru unknown
- 2007-03-30 ES ES10173208.9T patent/ES2569558T3/es active Active
- 2007-03-30 PL PL13172958T patent/PL2666859T3/pl unknown
- 2007-03-30 NZ NZ571569A patent/NZ571569A/en not_active IP Right Cessation
- 2007-03-30 EA EA201100810A patent/EA201100810A1/ru unknown
- 2007-03-30 US US12/295,960 patent/US8163708B2/en active Active
- 2007-03-30 EA EA201100812A patent/EA201100812A1/ru unknown
- 2007-03-30 EP EP18177355.7A patent/EP3431602A1/en active Pending
- 2007-03-30 SG SG201102154-0A patent/SG170773A1/en unknown
- 2007-03-30 EA EA201100811A patent/EA201100811A1/ru unknown
- 2007-03-30 EP EP10173208.9A patent/EP2261333B1/en active Active
- 2007-03-30 CN CN201210247597.0A patent/CN102851291B/zh active Active
- 2007-03-30 EP EP18203866.1A patent/EP3502255A1/en active Pending
- 2007-03-30 EP EP13172958.4A patent/EP2666859B1/en active Active
- 2007-03-30 MY MYPI20083769A patent/MY162210A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
WO2005061710A1 (en) * | 2003-12-23 | 2005-07-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
Also Published As
Publication number | Publication date |
---|---|
MY162210A (en) | 2017-05-31 |
EA201100810A1 (ru) | 2012-06-29 |
US8163708B2 (en) | 2012-04-24 |
EA201100812A1 (ru) | 2012-06-29 |
EP2666859A3 (en) | 2014-05-07 |
SG170773A1 (en) | 2011-05-30 |
EP2666859B1 (en) | 2019-01-02 |
EP2261333A3 (en) | 2014-03-19 |
NZ571569A (en) | 2011-09-30 |
EP2261333A2 (en) | 2010-12-15 |
CN102851291A (zh) | 2013-01-02 |
EA201100811A1 (ru) | 2012-06-29 |
SG10201406016SA (en) | 2014-11-27 |
EP3431602A1 (en) | 2019-01-23 |
EP2666859A2 (en) | 2013-11-27 |
PL2666859T3 (pl) | 2019-09-30 |
EA201100813A1 (ru) | 2012-06-29 |
EP3502255A1 (en) | 2019-06-26 |
US20100286234A1 (en) | 2010-11-11 |
ES2569558T3 (es) | 2016-05-11 |
EP2261333B1 (en) | 2016-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102851291B (zh) | 包含抗微小rna反义寡核苷酸的药物组合物 | |
US9133455B2 (en) | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | |
US8440637B2 (en) | Combination treatment for the treatment of hepatitis C virus infection | |
US20090118213A1 (en) | Rna antagonist compounds for the inhibition of apo-b100 expression | |
US20230348911A1 (en) | Antisense oligonucleotides for modulation of long noncoding rnas | |
CN101437942A (zh) | 包含抗微小rna反义寡核苷酸的药物组合物 | |
CN102203255A (zh) | 靶向hsp27的rna拮抗剂 | |
AU2012216487B2 (en) | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | |
AU2014208214A1 (en) | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | |
NZ571620A (en) | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | |
BRPI0709895A2 (pt) | composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SILATE CO., LTD. Free format text: FORMER OWNER: SANTARIS PHARMA AS Effective date: 20130902 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130902 Address after: Holm Hess, Denmark Applicant after: Roche Innovation Center Copenhagen A/S Address before: Holm Hess, Denmark Applicant before: SANTARIS PHARMA A/S |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Holm Hess, Denmark Patentee after: ROCHE INNOVATION CENTER COPENHAGEN A/S Address before: Holm Hess, Denmark Patentee before: SANTARIS PHARMA A/S |
|
TR01 | Transfer of patent right |
Effective date of registration: 20160808 Address after: Holm Hess, Denmark Patentee after: SANTARIS PHARMA A/S Address before: Holm Hess, Denmark Patentee before: Roche Innovation Center Copenhagen A/S |